Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQ05105 tablets for chronic graft-versus-host disease
CTR20240647Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rovadicitinib in chronic graft-versus-host disease (cGVHD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2024; status: active.
02
Drugs
rovadicitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20240647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240647.